Merck said in a Tuesday release that it is discontinuing the clinical development program for nemtabrutinib (MK-1026), an experimental oral drug being studied for blood cancers.
What happened
Merck announced on Tuesday that it is stopping the clinical trials evaluating nemtabrutinib, an investigational, non-covalent Bruton's tyrosine kinase (BTK) inhibitor taken orally, which had been studied in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, among other blood cancers. Shortly after, Reuters reported that Merck halted the trials following a risk assessment of the drug.
How the stock has moved
Merck shares closed at $143.37 on Tuesday. No trading could be observed after that close, so it is not yet clear how the stock has responded since the news broke.
| Measure | Value |
|---|---|
| Last close (Tuesday, November 17, 2026) | $143.37 |
| Market value at the close on Tuesday, November 17, 2026 | $353.44 billion |
Source: Stock quote; the close before the first report from our saved closes · as of November 17, 2026 at 4:58 PM ET · Shows what the stock did after the news was first reported, not why.
Its suppliers and customers
Company filings list Verona Pharma, Sidera Therapeutics and Doctor Fultz Pharma as suppliers to Merck. None of the three, which are not publicly listed, showed any trading activity since their last recorded close.
| Company | Role | Stock | Since last close |
|---|---|---|---|
| Verona Pharma | Supplier | Not listed | — |
| Sidera Therapeutics | Supplier | Not listed | — |
| Doctor Fultz Pharma | Supplier | Not listed | — |
Source: Relationships named in company filings (Earnings call transcript); stock quotes · as of November 17, 2026 at 4:58 PM ET · A supplier or customer moving the same day is not evidence that one move caused the other.